SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing extreme volatility due to recent CME Group margin requirement increases and impending Chinese export restrictions on silver, which are set to take effect. This has created a stark divide among traders, with many anticipating a massive short squeeze driven by perceived physical scarcity and industrial demand, while others warn of a speculative "pump and dump" and forced liquidations.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, a new treatment for motion-induced vomiting, notable for being the first in decades and for not causing drowsiness. The community is actively discussing its broader potential as an add-on therapy for GLP-1 induced nausea and vomiting, fueling significant speculation about a potential buyout from a major pharmaceutical company. This approval, coupled with other imminent regulatory decisions for jet lag and an antipsychotic drug, positions Vanda as a key topic among investors.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid choppy, low-volume trading as market participants grapple with mixed signals from recent Fed minutes regarding future rate policy. Community discussions are sharply divided, with bulls anticipating continued strength towards new highs and bears predicting an imminent correction, particularly as the anticipated "Santa Rally" appears to be largely absent.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending as the community highlights its deep strategic ties with Tether, including a significant ownership stake and substantial commitments for ad and cloud services. This partnership, alongside the acquisition of Northern Data AG greatly expanding Rumble's AI and cloud infrastructure, is fueling strong discussions about the stock being undervalued and ripe for a potential short squeeze given its high short interest.

Radware Ltd. engages in the provision of application security and delivery solutions for multi-cloud environments. The company’s cloud application, infrastructure, and API security solutions use AI-driven algorithms for precise, hands-free, real-time protection from the most sophisticated web, application, and DDoS attacks, API abuse, and bad bots. It operates through the following segments: Radware’s Core Business and Hawks’ Business. The Radware’s Core Business segment engages in providing cloud security-as-a-service products, application and data center security solutions, and application availability services. The Hawks’ Business segment provides cloud security solutions, including threat detection, entitlement management, and posture management. The company was founded by Yehuda Zisapel and Roy Zisapel on May 16, 1996 and is headquartered in Tel Aviv, Israel.

Radware

Radware is trending as its AI-powered cloud cybersecurity solutions garner attention, notably with the company's discovery of a critical zero-click AI vulnerability. Accelerated growth in cloud recurring revenue and strategic global expansions are fueling community discussions around its significant potential within the rapidly evolving threat landscape, alongside high growth expectations reflected in its valuation.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as an analyst recently lowered its price target due to anticipated weakness in crypto trading volumes, while the platform's holiday giveaways have ignited widespread user complaints about app glitches and minimal rewards. This has fueled divided community sentiment, with many expressing frustration over short-term performance and others holding a bullish long-term outlook for the fintech's role in digital finance. Observers are keenly watching how Robinhood navigates crypto market volatility and its strategic push into areas like prediction markets.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed is trending after reporting strong quarterly earnings, fueled by robust demand for its sleep and breathing devices and expanding margins, which has prompted several analyst upgrades. Simultaneously, intense community speculation centers on a potential acquisition or partnership with Incannex Healthcare ($IXHL), as its developing oral sleep apnea drug poses a significant disruptive threat to ResMed's traditional CPAP machine business.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI Crypto is experiencing strong community engagement, fueled by an overwhelmingly bullish sentiment around its "We All Gonna Make It" ethos. Discussions highlight the token's perceived long-term potential, with many actively accumulating and connecting its future success to broader crypto trends, especially within the Solana ecosystem.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is actively trending as it formally enters the U.S. regulatory process for deep-sea mining exploration licenses, highlighted by upcoming public hearings in late January. Investors are sharply divided between strong conviction in its national security importance for critical mineral supply and skepticism over its pre-revenue status and long-term production timeline, with many anticipating a rebound after recent volatility.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following a significant analyst upgrade that named it a top pick and added it to a "Conviction Buy" list. Community sentiment is largely bullish, focusing on strong average revenue per user growth and the platform's valuable human-created content for AI models, with many anticipating a technical breakout. This optimism is balanced by some skepticism regarding its high valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vincerx Pharma ($VINC) shares were in the spotlight over the weekend following the company’s proposed merger with Oqory, a privately-held, clinical-stage company that develops ADCs for the treatment of multiple oncology conditions, with retail sentiment staying strong.Vincerx stock was up 64% in after-hours trading session on Friday.Upon completion of the proposed merger, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%.Vincerx plans to reduce its workforce and undertake cost-control measures, the company said. As part of this workforce reduction, its CEO Dr. Ahmed Hamdy has stepped down but will remain as chairman. Dr. Raquel Izumi has stepped down as president and COO and taken over as acting CEO in a consulting capacity; Alexander Seelenberger has stepped down as CFO.Retail sentiment on Stocktwits has remained ‘bullish’ on the stock. Message volumes are in the ‘normal’ zone.<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_10_18_33_AM_bd88e280b0.png" alt="Screenshot 2024-12-30 at 10.18.33 AM.png" width="1256" height="302"><figcaption>VINC sentiment meter and message volumes on Dec 29 as of 11:45 pm ET</figcaption></figure><stembedurl>https://stocktwits.com/jlemx/message/598101092</stembedurl>The merger is subject to customary closing conditions and the completion of the minimum $20 million in financing, and the continued listing of Vincerx's common stock on Nasdaq.According to a Vincerx statement, the transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders.Additionally, certain Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches.The financing consists of about $1 million funded through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 funded on or prior to January 31, 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish

 Retail sentiment on Stocktwits has remained ‘bullish’ on the stock. 

Equity

Shares of Vincerx Pharma saw volatile trading on Wednesday, swinging between gains and losses after the company unveiled significant cost-cutting measures.&nbsp;The moves are aimed at advancing its VIP943 program, a cancer treatment for leukemias and myelodysplastic syndrome, the company said.Vincerx CEO Ahmed Hamdy reiterated the company’s commitment to VIP943, highlighting positive early results from the Phase 1 dose-escalation study.&nbsp;The trial showed promising safety and efficacy, with a relapsed AML patient achieving complete remission with incomplete blood count recovery (CRi) and a higher-risk MDS patient achieving complete remission with leukemic cells (CRL).&nbsp;Notably, the CRi patient showed significant improvement, with their bone marrow revealing only 1% cancer cells after seven months.To ensure the continued development of VIP943, Vincerx is taking aggressive steps to streamline operations and focus resources on the trial’s advancement.&nbsp;That includes a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.&nbsp;The company also announced plans to engage a financial advisor to guide the strategic review process.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VINC_sentiment_and_message_volume_Dec_4_196f59dc07.png" alt="VINC sentiment and message volume Dec 4 .png" width="1318" height="318"><figcaption>VINC sentiment and message volume Dec 4 as of 10:45 am ET | source: Stocktwits</figcaption></figure>Retail activity surrounding VINC surged, with message volume on Stocktwits reaching the second-highest level in the past year, while sentiment remained ‘bullish’.&nbsp;One watcher speculated that a reverse stock split or partnership deal could be in the works.<stembedurl>https://stocktwits.com/HoHoHoHum/message/594996367</stembedurl><a href="https://stocktwits.com/symbol/VINC">Vincerx’s stock</a> has struggled, losing over 75% of its value year-to-date.&nbsp;As of Oct. 31, the company had $8.4 million in cash and is actively pursuing partnerships to advance other oncology treatments, including VIP236 for solid tumors and enitociclib for leukemia.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail activity surrounding VINC surged, with message volume on Stocktwits reaching the second-highest level in the past year.

Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials 

The company's plans include a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

Current Price	$0.0125
Prev Close	$0.0125
Open	$0.0125
Dividend Yield	0.00%
50-Day Moving Average	$0.0136
Beta	0.01
Avg. Volume	2,155.89
PE Ratio	0.00

52-Week High	$5.04
52-Week Low	$0.0002
Market Capitalization	$65,428.00
EPS (Annual)	-$15.85
Price to Book	0.03
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

VINC
Vincerx Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VINC News

VINCVincerx Pharma Inc